.Pharmacolibrary.Drugs.ATC.N.N02AF02 .Pharmacolibrary.Drugs.ATC.N.N02AF02| name: | Nalbuphine |
| ATC code: | N02AF02 | route: | intravenous |
| n-compartments | 2 |
Nalbuphine is a synthetic opioid analgesic used to treat moderate to severe pain. It acts as a mixed agonist-antagonist at opioid receptors—agonist at kappa-opioid receptors and antagonist at mu-opioid receptors. It is primarily approved for use in the management and relief of pain, pre- and postoperative analgesia, and as a supplement to balanced anesthesia. It is currently approved for medical use in several countries.
Pharmacokinetic parameters reported in healthy adult volunteers after intravenous administration.
Nie, X, et al., & Wang, M (2023). Population pharmacokinetics of nalbuphine in patients undergoing general anesthesia surgery. Frontiers in pharmacology 14 1130287–None. DOI:10.3389/fphar.2023.1130287 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37025491
Pfiffner, M, et al., & Gotta, V (2022). Pharmacometric Analysis of Intranasal and Intravenous Nalbuphine to Optimize Pain Management in Infants. Frontiers in pediatrics 10 837492–None. DOI:10.3389/fped.2022.837492 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35311056
Korzekwa, K, et al., & Hawi, A (2024). A Continuous Intestinal Absorption Model to Predict Drug Enterohepatic Recirculation in Healthy Humans: Nalbuphine as a Model Substrate. Molecular pharmaceutics 21(9) 4510–4523. DOI:10.1021/acs.molpharmaceut.4c00424 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38956965